TNFRSF17 and precursor B-cell acute lymphoblastic leukemia: As shown in Figures 1B and 1C (right panel), all B-ALL patients express BAFF-R (mean 51.46%, range 5.09–96.5%), TACI (mean 33.15%, range 0.11–97.7%), whereas BCMA was seen in some patients (mean 26.56%; range 1.28–96.7%).